Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-10-13
First Named Inventor Michael		ael Peszynski
Art Unit		
Examiner Name		
Attorney Docket Numb	er	US040182

				Attorr	ney Doc	ket Number		US040182			
					U.S.	PATENTS	_			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code! Issue Date Of Release of Patentee or Applicant of cited Document Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear								
	1	5957850	A	1999-0	19-28	Marian					
	2	6059731	A	2000-0	15-09	Seward					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	nation pl	ease click the	Ac	dd button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LIC	CATIONS		Remove	
Examiner Cite No Publication Number Kind Publication Name of Patentee or Applicant Relevant Passages or Reference for Cited Document of cited Document											
	1										
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	n citatio	n information	ple	ase click the Ad	d butto		
				FORE	GN PAT	TENT DOCUM	AE)	NTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	A	Name of Patente Applicant of cited Document		Pages,Columns,Lir where Relevant Passages or Relevant Figures Appear	76
	1										
If you wish	h to a	dd additional Foreign F	atent Do	cument	t citation	information p	olea	ase click the Add	buttor	Add	
			NON	I-PATE	NT LITE	RATURE DO	CL	UMENTS		Remove	

	Application Number		
NEODMATION DIOOLOGUEE	Filing Date		2006-10-13
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Michi	ael Peszynski
Not for submission under 37 CFR 1.99)	Art Unit		
Not for Submission shade or or it is say	Examiner Name		
	Attorney Docket Number	er	US040182

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year USPTIO_CODY or MPEP 901.04. 2 Either office that issued the document, by the bro-bitter code (WIPO Standard ST.3). 3 For disparence patient bounders, by exaction of the year of the Emperor most procedule has early a time-for office patient bounders. If which office the properties with the properties are indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English tanguage branisation is attached.

Application Number Filing Date 2006-10-13 Filing Date 12006-10-13 Filing Date 2006-10-13 Filing Date Filing Date Filing Date 12006-10-13 Filing Date Filing Date 12006-10-13 Filing Date Filing Date 12006-10-13 Filing Date 1

CERTIFICATION STATEMENT

ricase see 31	CFR 1.07 all	a 1.50 to make the	appropriate selection	(>).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(vic).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Aaron Waxier/	Date (YYYY-MM-DD)	2006-10-13
Name/Print	Aaron Waxier	Registration Number	48027

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.